XML 92 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1

ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenues from Collaboration and Licensing Agreements

Revenues from collaboration and licensing agreements as a percentage of total revenues were as follows:

			Year Ended December 31,
			2023						2022						2021
Biogen MA, Inc.			77		%				26		%				38		%
Kite Pharma, Inc.			12		%				35		%				23		%
Novartis Institutes for BioMedical Research, Inc.			7		%				36		%				34		%
Other licensing agreements			4		%				3		%				5		%

Schedule of Percentage of Accounts Receivable by Collaboration Partners

As of December 31, 2023 and 2022, the percentage of accounts receivable by collaboration partners who individually accounted for 10% or more of accounts receivable were as follows:

			As of December 31,
			2023						2022
Sigma-Aldrich Corporation			78		%				—		%
Kite Pharma, Inc.			18		%				19		%
Novartis Institutes for BioMedical Research, Inc.			—		%				59		%
Biogen MA, Inc.			—		%				14		%

Schedule of Cash and Cash Equivalents

A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):

			As of December 31,
			2023						2022						2021
Cash and cash equivalents			$	45,204					$	100,444					$	178,872
Non-current restricted cash			1,500						1,500						1,500
Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows			$	46,704					$	101,944					$	180,372

Schedule of Restricted Cash

A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):

			As of December 31,
			2023						2022						2021
Cash and cash equivalents			$	45,204					$	100,444					$	178,872
Non-current restricted cash			1,500						1,500						1,500
Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows			$	46,704					$	101,944					$	180,372

X

- Definition

Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues

+ References

No definition available.

+ Details

Name:	sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-8

+ Details

Name:	us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration